Building a Differentiated Obesity Biotech

Episode notes

Metsera CEO Whit Bernard joins Venrock's Nimish Shah to discuss how the company's ultra-long acting GLP-1 program helped position it as a strategic standout in the obesity market. The conversation covers the bidding war between major pharma players, lessons in first-principles company building, and why the next decade of biotech could reward high-volume, accessible innovation.

• Healthcare Prognosis 202672 / 100
• Arca's AI-First Vision for Human-First Wealth Management
• The Long Game of Building Breakthrough Biotech
• SmithRx's Mission to Break the Drug Pricing Black Box
• Pursuit over Podium: Rethinking Excellence with Brad Stulberg